Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Aptose Biosciences Inc TSX: APS-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

Aptose Reports Results for the Second Quarter 2021
- GlobeNewswire - Tue Aug 3, 3:01PM CDT
GlobeNewswire - CMTX
Tue Aug 3, 3:01PM CDT
- Conference call and webcast at 5:00 pm EDT today -
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
- GlobeNewswire - Tue Jul 20, 3:01PM CDT
GlobeNewswire - CMTX
Tue Jul 20, 3:01PM CDT
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended June 30, 2021, and provide a corporate update on Tuesday, August 3, 2021, after the close of the market.
Aptose Presents Highlights from EHA During Corporate Update Event
- GlobeNewswire - Fri Jun 11, 6:55AM CDT
GlobeNewswire - CMTX
Fri Jun 11, 6:55AM CDT
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET, in concurrence with participation at the EHA2021 Virtual Congress (EHA). The event is focused on the current clinical status of luxeptinib, Aptose's oral, first-in-class FLT3 and BTK kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies. The live and archived webcast of the presentation is available on Aptose's website here.
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
- GlobeNewswire - Tue Jun 1, 4:43PM CDT
GlobeNewswire - CMTX
Tue Jun 1, 4:43PM CDT
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 1, 2021 (the "Meeting"). A total of 72.83% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting.
Aptose to Hold Corporate Update Friday, June 11th
- GlobeNewswire - Thu May 27, 6:30AM CDT
GlobeNewswire - CMTX
Thu May 27, 6:30AM CDT
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS
Aptose to Present at Upcoming Investor Conferences
- GlobeNewswire - Wed May 12, 6:30AM CDT
GlobeNewswire - CMTX
Wed May 12, 6:30AM CDT
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences:
Aptose Reports Results for the First Quarter 2021
- GlobeNewswire - Tue May 4, 3:01PM CDT
GlobeNewswire - CMTX
Tue May 4, 3:01PM CDT
- Conference call and webcast at 4:30 pm EDT today -
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
- GlobeNewswire - Mon Apr 26, 3:02PM CDT
GlobeNewswire - CMTX
Mon Apr 26, 3:02PM CDT
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market.
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
- GlobeNewswire - Thu Apr 8, 6:30AM CDT
GlobeNewswire - CMTX
Thu Apr 8, 6:30AM CDT
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity's 2021 Horizons in Oncology Virtual Conference:
Aptose Reports Results for the Fourth Quarter and Full Year 2020
- GlobeNewswire - Tue Mar 23, 3:01PM CDT
GlobeNewswire - CMTX
Tue Mar 23, 3:01PM CDT
- Conference call and webcast at 5pm EDT today -

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies